Canaccord Genuity analyst Michelle Gibson raised the price target on Ascendis Pharma (NASDAQ: ASND) to $132.00 (from $84.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE